Spark hemophilia B gene therapy clears test en route to Pfizer-sponsored phase 3

Spark Therapeutics has presented data on hemophilia B patients who received a version of its gene therapy manufactured using a modified process. Early data on the patients suggest the new batch of the…
Read the full story: FierceBiotech: Biotech